Research explains limits of cancer immunotherapy drugs

October 26, 2015

Immunotherapy treatments have proven wildly successful in treating some patients with cancer. But despite this success, the majority of patients do not respond to the treatments.

A new study from the University of Michigan Comprehensive Cancer Center reveals molecular changes within the tumor that are preventing the immunotherapy drugs from killing off the .

Clinical trials with PD-L1 and PD-1 blockade suggested that tumors with a high number of inflammation-causing T cells were more responsive to the immunotherapy-based PD-L1 and PD-1 inhibitors. Tumors with low inflammation, or low T cells, were less responsive. But what controls T cells in the tumor microenvironment is poorly understood.

"We defined a molecular mechanism to explain why some tumors are inflamed and others are not - and consequently why some will be responsive to therapy and others not," says senior author Weiping Zou, M.D., Ph.D.

"If we can reprogram this epigenetic mechanism, then the therapy might work for more patients," says Zou, Charles B. de Nancrede Professor of Surgery, Immunology and Biology at the University of Michigan Medical School.

Zou's group was the first to show PD-L1 expression, regulation and functional blockade in in the human cancer microenvironment.

In this study, published in Nature, researchers studied human and mouse models of . They applied epigenetic drugs and found that the numbers of T in the tumor increased. They also saw that the epigenetic drugs synergized the anti-tumor effect of PD-L1 blockade in their models.

"We hope this could be developed into a clinical trial testing a combination of PD-L1 and PD-1 blockade with epigenetic therapy. We want to see if we can make the responders more responsive and turn the non-responders into responders," Zou says.

Explore further: Identifying protein that may predict response to PD-1 immunotherapy for melanoma

More information: Nature, "Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy," published online Oct. 26, 2015. DOI: 10.1038/nature15520

Related Stories

Study points to potential new lung cancer therapy

April 20, 2015

New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.

Recommended for you

Targeted drug shows promise in rare advanced kidney cancer

June 23, 2017

Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Shapoval
not rated yet Nov 10, 2015
Father of Oncology Explains Limits of Cancer Immunotherapy Drugs. Immunotherapy is the fruition of a century-old idea. But what if cancer loves iron (cancer is a disease of iron-overloaded cells); researchers love money? Direct intratumoral injections of iron-deficiency agents/substances (ceramic needles) are needed when tumors/metastases cannot be removed with surgery (ceramic blades), the Father of Oncology explains. Unfortunately, the immune system (which is made up of special cells, proteins, tissues, and organs) cannot recognize and attack cancerous cells (iron-overloaded cells). Iron overload is not a crime, iron-overloaded cells are not our enemies, the immune system thinks. Primary tumors always develop at body sites of excessive iron deposits; such deposits can be inherited or acquired, the Father of Oncology thinks. http://www.medica...s/191369 ; https://plus.goog...SqVBV9DS ; https://www.faceb...apoval.5

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.